Company Description
C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins.
Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
The company is also developing oncology product candidate, CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor, with an L858R mutation in non-small cell lung cancer; and new degraders focused on inflammation, neuroinflammation, and neurodegeneration.
It has strategic collaborations F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGAA.
The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Oct 2, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 110 |
| CEO | Andrew Hirsch |
Contact Details
Address: 490 Arsenal Way, Suite120 Watertown, Massachusetts 02472 United States | |
| Phone | 617 231 0700 |
| Website | c4therapeutics.com |
Stock Details
| Ticker Symbol | CCCC |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 1662579 |
| CUSIP Number | 12529R107 |
| ISIN Number | US12529R1077 |
| Employer ID | 47-5617627 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Andrew J. Hirsch M.B.A. | Chief Executive Officer, President and Director |
| Dr. Kenneth C. Anderson M.D., Ph.D. | Co-Founder, Independent Director and Member of Scientific Advisory Board |
| Kendra Adams | Chief Financial Officer and Head of Corporate Affairs and Treasurer |
| Dr. Leonard M. J. Reyno M.D. | Chief Medical Officer |
| Dr. Nathanael S. Gray Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Mark Mossler | Chief Accounting Officer |
| Paige Mahaney Ph.D. | Chief Scientific Officer |
| Courtney Solberg | Senior Manager of Investor Relations |
| Kelly A. Schick | Chief People Officer |
| Dr. Isabel Chiu Ph.D. | Senior Vice President of Strategic Alliances and Business Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 9, 2026 | 144 | Filing |
| Feb 26, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Feb 26, 2026 | 10-K | Annual Report |
| Feb 26, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 12, 2026 | SCHEDULE 13G/A | Filing |
| Feb 11, 2026 | SCHEDULE 13G/A | Filing |
| Jan 14, 2026 | 8-K | Current Report |
| Dec 10, 2025 | EFFECT | Notice of Effectiveness |